Close Menu

NEW YORK – Biopharmaceutical company DelMar Pharmaceuticals said on Tuesday that it has enrolled 22 out of a planned 24 patients in an arm of an ongoing Phase II trial studying VAL-083 as a maintenance treatment in newly diagnosed, MGMT-unmethylated glioblastoma multiforme.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.